Zelia Correa is an Ophthalmology physician affiliated with University of Miami. OpenAlex indexes 273 publications with 3,153 citations (h-index 25).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
900 NW 17th St
Miami, FL 331361119
Telephone
305-326-6000Provider last certified this registry record 29 Oct 2024.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Immunocore LimitedProgram year20252 payments
- Ocular Therapeutix, Inc.Program year20251 payment
- Regeneron Healthcare Solutions, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
52.7%Aminoglycoside Antibacterial30.2%Neomycin-Polymyxin-Dexameth100%Part D≥29 patientsCorticosteroid14.2%Prednisolone Acetate100%Part D≥16 patients+ 1 more class in this area
Cancer & immunology
35.5%Vascular Endothelial Growth Factor Inhibitor35.5%Aflibercept100%Part B, office-administered≥11 patientsMusculoskeletal
11.8%Cyclooxygenase Inhibitor11.8%Ketorolac Tromethamine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2021–2021 per NIH RePORTER. The latest:
- Molecular Predictive Testing in Ocular Melanoma
University of Miami School of Medicine
FY2021$626,898R01CA125970
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Myerburg, MD
University of Miami
Thomas Hooton, MD
University of Miami
Harry Flynn, MD
University of Miami
Alan Wein, MD
University of Miami
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”